Barclays raised the firm’s price target on Insmed (INSM) to $237 from $231 and keeps an Overweight rating on the shares as part of a Q1 preview. The firm sees a strong near-term Brinsupri launch and longer term a meaningful opportunity for Arikayce. It believes Insmed are mispriced at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: